Abiopharma

🔍 Deng Conglin (Director)

Company: Abits Group Inc (ABTS)

Report Date: 2026-04-15

Detailed Transactions and Holdings:

• Acquired 40,000 shares of Ordinary Shares (Direct)
  Date: 2026-04-15 | Code: M | equity_swap_involved: 0 | shares_owned_after: 77,355.00 | transaction_form_type: 4 | Footnotes: F1
• Holds 0 shares of Ordinary Shares (Direct)
  Date: 2026-04-15 | Code: H | nature_of_ownership: By Bridgeforrest (BVI) Inc | shares_owned_after: 10,666.00 | Footnotes: F2
• Holds 0 shares of Ordinary Shares (Direct)
  Date: 2026-04-15 | Code: H | nature_of_ownership: By trust | shares_owned_after: 373,333.00 | Footnotes: F3
• Holds 0 shares of Preferred Shares (Direct)
  Date: 2026-04-15 | Code: H | nature_of_ownership: By Bridgeforrest (BVI) Inc | shares_owned_after: 333,333.00 | Footnotes: F2
• Sold 40,000 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-15 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F4, F5, F5

Footnotes:

• F1: Restricted stock units convert into common stock on a one-for-one basis.
• F2: The securities reported herein are held by Bridgeforrest (BVI) Inc, which is an entity controlled by the Reporting Person.
• F3: The securities reported herein are owned directly by a trust, of which the Reporting Person's family members are the beneficiaries. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported shares for purposes of Section 16 or for any other purpose.
• F4: Each restricted stock unit represents the right to receive one share of the Issuer's ordinary shares upon settlement.
• F5: These restricted stock units vested on December 31, 2025.